NCT01038453

Brief Summary

The purpose of this study is to determine whether a daily supplement of vitamin D, taking before and during pregnancy, effects child birth weight, pre- and postpartum complication and bone mineral density during lactation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2009

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2009

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

December 18, 2009

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 24, 2009

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

November 4, 2011

Status Verified

November 1, 2011

Enrollment Period

2 years

First QC Date

December 18, 2009

Last Update Submit

November 3, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Birth Weight

    0-24 hours after delivery of the child

Secondary Outcomes (4)

  • Post-partum effects of vitamin D supplement on maternal bone mineral density (BMD).

    Day 1 to 4 months after delivery.

  • Infections of the newborn

    Day 1 of the child to 16 weeks after birth.

  • Growth of the newborn measured by weight, crown-heel length and head circumference

    Day 1 of the child to 16 weeks after birth

  • Time to accomplish pregnancy

    0-12 months

Study Arms (3)

Cholecalciferol (Vitamin D3) 35 µg

ACTIVE COMPARATOR

Dietary Supplement: Cholecalciferol (Vitamin D3) 35 µg per day

Dietary Supplement: Cholecalciferol 35 µg per day

Cholecalciferol (Vitamin D3) 70 µg

ACTIVE COMPARATOR

Dietary supplement: Cholecalciferol (Vitamin D3) 70 µg per day

Dietary Supplement: Cholecalciferol (Vitamin D3) 70 µg

placebo

PLACEBO COMPARATOR
Other: placebo tablet

Interventions

Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day. In total 2 tablets per day per participant from Baseline to 16 weeks after delivery.

Cholecalciferol (Vitamin D3) 35 µg

placebo 2 tablet, once a day,

placebo

Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day. In total 2 tablets per day per participant from Baseline to 16 weeks after delivery.

Cholecalciferol (Vitamin D3) 70 µg

Eligibility Criteria

Age20 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • P-OH25-vitamin D \< 50 nmol/l
  • Woman age 30-35 years
  • In good general health

You may not qualify if:

  • Infertility
  • Intake of 400 IU or more Vitamin D/day
  • Cancer
  • Alcohol or drug abuse
  • Calciummetabolic disturbances
  • Spontaneous abortion within last 6 month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Aarhus, Aarhus Universityhospital

Aarhus, Denmark

RECRUITING

Related Publications (1)

  • Palacios C, Kostiuk LL, Cuthbert A, Weeks J. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2024 Jul 30;7(7):CD008873. doi: 10.1002/14651858.CD008873.pub5.

MeSH Terms

Conditions

Birth WeightVitamin D Deficiency

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

Body WeightSigns and SymptomsPathological Conditions, Signs and SymptomsAvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Gitte Bloch Rasmussen, MD

    Aarhus University Hospital

    PRINCIPAL INVESTIGATOR
  • Lars Rejnmark, MD, PhD, Drmed.

    Aarhus University Hospital

    STUDY DIRECTOR

Central Study Contacts

Gitte Bloch Rasmussen, MD

CONTACT

Lars Rejnmark, MD, PhD, DrMed

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2009

First Posted

December 24, 2009

Study Start

December 1, 2009

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

November 4, 2011

Record last verified: 2011-11

Locations